|Day's Range||41.130 - 41.290|
|52 Week Range||36.580 - 47.820|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
Bristol-Myers Squibb’s (BMY) latest drug Opdivo was the seventh drug to be approved by the FDA for the treatment of melanoma.
In 1Q17, Allergan's US Specialized Therapeutics segment revenues rose 14.1% to $1.48 billion, as compared to $1.30 billion in 1Q16.
Shares of Valeant Pharmaceuticals International Inc. soared 11% in premarket trade Tuesday, after the drug maker beat first-quarter profit expectations, although revenue came up shy. The company swung ...